[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inspiremd Inc (NSPR)

Inspiremd Inc (NSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,553
  • Shares Outstanding, K 46,839
  • Annual Sales, $ 8,980 K
  • Annual Income, $ -48,790 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta 0.78
  • Price/Sales 3.66
  • Price/Cash Flow N/A
  • Price/Book 0.75
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings $-0.16 on 05/04/26
  • Next Earnings Date 08/03/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Options Overview Details

View History
  • Implied Volatility 409.95% (+111.29%)
  • Historical Volatility 53.74%
  • IV Percentile 59%
  • IV Rank 41.19%
  • IV High 953.88% on 06/15/26
  • IV Low 28.94% on 09/04/25
  • Expected Move (DTE 28) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 566
  • Open Int (30-Day) 558
  • Expected Range 0.6949 to 0.6949

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.20
  • Number of Estimates 1
  • High Estimate $-0.20
  • Low Estimate $-0.20
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6300 +10.30%
on 06/26/26
0.7399 -6.08%
on 06/25/26
-0.0061 (-0.87%)
since 06/23/26
3-Month
0.6300 +10.30%
on 06/26/26
1.3091 -46.92%
on 04/27/26
-0.5851 (-45.71%)
since 04/23/26
52-Week
0.6300 +10.30%
on 06/26/26
2.9319 -76.30%
on 08/04/25
-1.7851 (-71.98%)
since 07/23/25

Most Recent Stories

More News
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST)  – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...

RXST : 5.37 (-0.37%)
KMTS : 21.57 (+3.26%)
NSPR : 0.6949 (-0.01%)
AXNX : 70.98 (+0.75%)
InspireMD Initiates CGUARDIANS II Clinical Trial for CGuard Prime Carotid Stent System

InspireMD enrolls first patient in CGUARDIANS II trial for CGuard Prime Stent System in TCAR procedures.Quiver AI SummaryInspireMD, Inc. has announced the enrollment of the first patient in its CGUARDIANS...

NSPR : 0.6949 (-0.01%)
InspireMD, Inc. Appoints Scott R. Ward to Board of Directors to Drive Stroke Prevention Innovation

InspireMD appoints Scott R. Ward to its Board, enhancing expertise ahead of potential U.S. approval for CGuard Prime stent.Quiver AI SummaryInspireMD, Inc. has announced the appointment of Scott R. Ward,...

NSPR : 0.6949 (-0.01%)
NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development

NAMSA , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc . (Nasdaq: NSPR), developer of the CGuardâ„¢ Embolic Prevention...

NSPR : 0.6949 (-0.01%)
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

- Generated 47.8% growth in CGuardâ„¢ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuardâ„¢ EPS, including a...

NSPR : 0.6949 (-0.01%)
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR),...

NSPR : 0.6949 (-0.01%)

Business Summary

InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous...

See More

Key Turning Points

3rd Resistance Point 0.7433
2nd Resistance Point 0.7316
1st Resistance Point 0.7133
Last Price 0.6949
1st Support Level 0.6833
2nd Support Level 0.6716
3rd Support Level 0.6533

See More

52-Week High 2.9319
Fibonacci 61.8% 2.0526
Fibonacci 50% 1.7810
Fibonacci 38.2% 1.5093
Last Price 0.6949
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.